Aquestive Therapeutics Inc (NASDAQ:AQST) shares, rose in value on Wednesday, July 09, with the stock price up by 8.97% to the previous day’s close as strong demand from buyers drove the stock to $4.01.
Actively observing the price movement in the last trading, the stock closed the session at $3.68, falling within a range of $3.7 and $4.025. The value of beta (5-year monthly) was 1.933. Referring to stock’s 52-week performance, its high was $5.80, and the low was $2.12. On the whole, AQST has fluctuated by 12.64% over the past month.
With the market capitalization of Aquestive Therapeutics Inc currently standing at about $398.31 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-12.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that AQST’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of Hold while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of AQST currently trading nearly 16.22% and 31.80% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 74.00, while the 7-day volatility ratio is showing 5.82% which for the 30-day chart, stands at 6.52%. Furthermore, Aquestive Therapeutics Inc (AQST)’s beta value is 1.97.
A comparison of Aquestive Therapeutics Inc (AQST) with its peers suggests the former has fared considerably weaker in the market. AQST showed an intraday change of 8.97% in last session, and over the past year, it grew by 12.64%%.
Data on historical trading for Aquestive Therapeutics Inc (NASDAQ:AQST) indicates that the trading volumes over the past 10 days have averaged 1.26 and over the past 3 months, they’ve averaged 1.51 million. According to company’s latest data on outstanding shares, there are 99.32 million shares outstanding.
Nearly 7.70% of Aquestive Therapeutics Inc’s shares belong to company insiders and institutional investors own 42.58% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 12.0 million shares as on 2025-06-13, resulting in a short ratio of 5.96. According to the data, the short interest in Aquestive Therapeutics Inc (AQST) stood at 1434.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 9.84 million. The stock has risen by 61.69% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the AQST stock heading into the next quarter.
